Publications, Posters and Presentations

ANNUAL

REPORT 2024

Publications, Posters and Presentations

ANNUAL

REPORT 2024

ANNUAL REPORT 2024

Publications, Posters and Presentations

PUBLICATIONS

The Lancet, 3 April 2023
ENZAMET

Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial (and supplementary appendix)

Christopher J Sweeney, et al.

ASCO, 16 June 2023

Patterns of Relapse in Australian Patients With Clinical Stage 1 Testicular Cancer: Utility of the Australian and New Zealand Urogenital and Prostate Cancer Trials Group Surveillance Recommendations

Ciara Conduit, et al.

BJU International, 18 September 2023

DIPPER

The Dedicated Imaging Post-Prostatectomy for Enhanced Radiotherapy outcomes (DIPPER) trial protocol: a multicentre, randomised trial of salvage radiotherapy versus surveillance for low-risk biochemical recurrence after radical prostatectomy

Matthew J. Roberts, et al.

European Association of Urology, 20 September 2023

PCRMIB

Pembrolizumab with Chemoradiation as Treatment for Muscle-invasive Bladder Cancer: Analysis of Safety and Efficacy of the PCR-MIB Phase 2 Clinical Trial (ANZUP 1502)

Andrew Weickhardt, et al.

BJU International, 1 March 2024

UNISoN

A phase II trial of nivolumab followed by ipilimumab and nivolumab in advanced non-clear-cell renal cell carcinoma

Ciara Conduit, et al.

The Lancet, 4 January 2024

TheraP

Overall survival with [¹⁷⁷Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial

Michael S Hofman, et al.

BJU International, 3 February 2024

DIPPER

The Dedicated Imaging Post-Prostatectomy for Enhanced Radiotherapy outcomes (DIPPER) trial protocol: a multicentre, randomised trial of salvage radiotherapy versus surveillance for low-risk biochemical recurrence after radical prostatectomy

Matthew J. Roberts, et al.

ScienceDirect, 27 February 2024

FASTTRACK II

Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trial

Prof Shankar Siva, et al.

BJU International, 1 March 2024

UNISoN

A phase II trial of nivolumab followed by ipilimumab and nivolumab in advanced non-clear-cell renal cell carcinoma

Ciara Conduit, et al.

BJU International, 13 March 2024

SUBDUE-1

The SUB-urothelial DUrvalumab InjEction-1 (SUBDUE-1) trial: first-in-human trial in patients with bladder cancer

Dickon Hayne, et al.

PRESENTATIONS AND POSTERS

ASCO 2023, 2 Jun 2023

GUIDE (ANZUP 1903) Abstract #TPS5099

A randomized non-comparative phase II trial of biomarker driven intermittent docetaxel versus standard-of-care docetaxel in metastatic castration-resistant prostate cancer (ANZUP 1903)

First Author: Ciara Conduit

ASCO 2023, 2 Jun 2023

BCGMM (ANZUP 1301) Abstract #TPS4617

Adding mitomycin (MM) to Bacillus Calmette-Guérin (BCG) as adjuvant intravesical therapy for high-risk, non muscle-invasive urothelial bladder cancer (NMIBC) (BCGMM; ANZUP 1301)

First Author: D Hayne

ASCO 2023, 2 Jun 2023

P3PEB (ANZUP 1302) Abstract # TPS5102

P3 BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumours (GCTs)

First Author: DS Zebic

ASCO 2023, 2 Jun 2023

TheraP (ANZUP 1603)

Effects of [177Lu]Lu-PSMA-617 on overall survival in TheraP (ANZUP 1603) versus VISION randomized trials: An Exploratory Analysis

First Author: Yu Yang Soon

ASCO 2023, 2 Jun 2023

CLIMATE (ANZUP 1906) Abstract #TPS5100

CLIMATE: Assessing the Clinical utility of miR-371a-3p as a marker of residual disease in Clinical Stage 1 Testicular Germ Cell Tumour following orchidectomy (ANZUP 1906)

First Author: Ciara Conduit

ESMO 2023, 24 October 2023

KEYPAD (ANZUP 1601) Abstract #1284

Denosumab and pembrolizumab in advanced clear cell renal carcinoma: KeyPAD (ANZUP 1601)

First Author: C Gedye

ESMO 2023, 24 October 2023

ENZAMET (ANZUP 1304) Abstract #1792P

Effects of enzalutamide on overall survival ± early docetaxel, in participants aged less than 70 yrs versus greater than or equal to 70 yrs in ENZAMET (ANZUP 1304)

First Author: L Horvath

ASCO GU 2024, 29 January 2024

DASL-HiCaP (ANZUP 1801) Abstract #328

Baseline disease characteristics of participants enrolled on ENZARAD (ANZUP 1303) and DASL-HiCaP (ANZUP 1801) trials of highly effective androgen receptor antagonists in high-risk localized or locally advanced prostate cancer (PCa)

First Author: Tamim Niazi

ASCO GU 2024, 29 January 2024

ENZAMET (ANZUP 1304) Abstract #1304

Radiographic progression without PSA progression in metastatic hormone-sensitive prostate cancer (mHSPC): a retrospective analysis from the ENZAMET trial (ANZUP 1304)

First Author Ian D. Davis

ASCO GU 2024, 29 January 2024

P3BEP (ANZUP 1302) Abstract #TPS524

TRIALS IN PROGRESS -P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for individuals aged 11-45 years with intermediate and poor-risk metastatic germ cell tumours

First Author: B Mak

ASCO GU 2024, 29 January 2024

UNICAB (ANZUP 1802) Abstract #437054

UNICAB: Cabozantinib In Locally Advanced Or Metastatic Non‐Clear Cell Renal Cell Carcinoma Post Immunotherapy or in those Unsuitable For Immunotherapy (ANZUP 1802)

First Author: David W. Pook